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Summary
Background.— A programme for quality assurance and prevention of infection risk during
implantation of cardiac medical devices (pacemakers and deﬁbrillators) was set up in our
hospital.
Aim.— We sought to assess surgical site infection rate and compliance with infection-control
practices (principally antibiotic prophylaxis).
Methods.— Surgical site infections associated with implanted medical devices were monitored
in patients during a 6-month period and a 1-year follow-up. Professional practices concerning
the use of prophylactic antibiotics in surgery were assessed.
Results.— The surgical site infection rate was 2.3%. Overall compliance was 45% for the use of
antibiotic prophylaxis.
Conclusions.— Optimal compliance with antibiotic prophylaxis was not reached in the present
series, which demonstrated a surgical site infection rate of 2.3%. More effort must be made to
achieve full compliance with preventive measures in the implantation of medical devices.
© 2011 Published by Elsevier Masson SAS.
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Résumé
Introduction.— Un programme d’assurance qualité et de prévention du risque infectieux
concernant les dispositifs médicaux implantés (DMI) en cardiologie (pacemaker et déﬁbrilla-
teurs) a été mis en place dans notre établissement.
Population et méthode.— Une surveillance des infections de site opératoire (ISO) sur DMI a été
réalisée chez les patients inclus au cours d’un semestre et après un suivi d’un an. Il a égale-
ment été réalisé une évaluation de pratiques professionnelles portant sur l’antibioprophylaxie
opératoire.
Résultats.— Le taux d’infection de site opératoire est de 2,3 %. La conformité globale portant
sur l’antibioprophylaxie est de 45%.
Conclusion.— L’observance des bonnes pratiques en antibioprophylaxie periopératoire n’est pas
optimale dans cette série dans laquelle le taux d’infection du site opératoire est de 2,3 %. Les
efforts doivent être poursuivis aﬁn d’améliorer les taux d’observances des principales recom-
mandations relatives à la maîtrise du risque infectieux lors de la mise en place de dispositifs
cardiologiques implantables.
© 2011 Publie´ par Elsevier Masson SAS.
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abbreviations
PP assessment of professional practice
SA American Society of Anesthesiologists
CD implantable cardioverter-deﬁbrillator
MD implantable medical device
SI surgical site infection
AISIN Réseau d’alerte, d’investigation et de surveillance
des infections nosocomiales
NIS National Nosocomial Infection Surveillance
ICD automatic implantable cardioverter-deﬁbrillator
RSA methicillin-resistant Staphylococcus aureus
ntroduction
ince 2004, APP has been obligatory for French doctors
1]. APP consists of ‘‘the analysis of professional prac-
ice with respect to recommendations and according to a
ethod drawn up or validated by the Haute Autorité de
anté, and includes the implementation and monitoring of
mprovement actions’’ [2], such as antibiotic prophylaxis,
reoperative preparation of patient’s skin and presurgical
lcohol-based hand rub. Meanwhile, SSI surveillance has
een strongly recommended in the French surveillance and
nfection control programme. Although IMDs in cardiology
re not speciﬁcally targeted, the assessment of SSI rates in
his population is of great interest.
Up to 2008, the cardiology suites at Hôpital Rangueil used
or the implantation of IMDs did not meet all of the char-
cteristics of an operating theatre, in particular regarding
ir quality. In October 2008, the rhythmology and cardiac
timulation team moved into new premises that possessed
ll of these characteristics. A quality assurance programme,
‘Good hygiene practice in the operating theatre’’, was
hen proposed and was implemented in September 2008.
he programme comprised a revision of the protocol for
rophylactic antibiotic use in surgery and its validation by
he anti-infection committee; and information provided to
i
w
t
che rhythmology team on preoperative preparation of a
atient’s skin according to French guidelines, and the use by
he surgical team of a presurgical alcohol-based hand rub,
s recommended by French guidelines.
In 2009, after the rhythmology and cardiac stimulation
eam had adapted to the new premises and techniques, the
nfection control team, in cooperation with the rhythmology
nd cardiac stimulation unit, carried out an assessment of
hese professional practices, combined with epidemiological
onitoring of SSIs. We sought to describe the results of IMD
nfection monitoring and to evaluate antibiotic prophylaxis
ractices.
opulation and method
SI surveillance
onsecutive patients were prospectively included from 17
ebruary 2009 to 15 August 2009. Inclusion criteria were:
rst implantation, deﬁned as implantation in a new patient;
rst contralateral implantation in a patient already having
eceived an IMD on the opposite side; and reimplantation
erformed > 30 days after the initial implantation. Exclusion
riteria were: simple reinterventions on the scar; IMDs not
mplanted by the rhythmology team; IMD extraction; rein-
erventions in the same surgical site < 30 days after the ﬁrst
mplantation.
Exhaustivity was checked by the infection-control team
y cross-reference with the roster of operations performed
n the rhythmology suite.
ata collection
standardized form was adapted from the PEOPLE cohort,
recent multicentre survey of pacemaker SSIs [3], takingnto account the recommendations of the national net-
ork of surgical site monitoring [4]. The form comprised
he following variables: age, sex, ASA score, Altemeier’s
lass of contamination, procedure duration, type of IMD
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aSurveillance of infection risk of implanted devices
and classical risk factors for infection (anticoagulants, valve
prosthesis, resuscitation, admission to intensive care unit,
hyperthermia) [3]. The use and timing of antibiotic prophy-
laxis was also recorded. Follow-up data were obtained by the
infection control team from hospital records and suspected
infections were analysed by the referring cardiologists (PM,
AH, AD, MD).
Deﬁnition of SSI
As beﬁts the implantation of foreign material [5], SSI was
deﬁned as any infection occurring in the year following
implantation. All patients were followed for 1-year after
implantation. SSI was deﬁned as pus discharge from the
wound, irrespective of microorganism identiﬁcation or deep
infection of the surgical site. Because the diagnosis of
endocarditis or infection of the leads is elusive, even in
cases of haematogenic infection [6], conﬁrmation by tran-
soesophageal echocardiography was obtained systematically
for any suspicious biological (inﬂammatory syndrome, blood
cultures) or clinical symptoms. Patient characteristics (age,
sex), length of hospital stay, type of implantation (total ﬁrst
implantation, total reintervention), type of IMD (total pace-
maker, ICD and total Holter), characteristics of interventions
(emergency, procedure duration, ASA class, contamination
class, NNIS score), compliance to antibiotic prophylaxis,
and risk factors known from the literature (anticoagu-
lant or antiplatelet treatment, valve prosthesis, previous
resuscitation, intensive care stay, preoperative tempera-
ture > 37.5 ◦C) were recorded.
NNIS scores were calculated from the ASA score, which
reﬂects performance status (range 1—5), Altemeier’s class
of wound contamination, and duration of the surgical pro-
cedure classiﬁed in two classes according to the 75th
percentile of duration of the present series.
Assessment of antibiotic prophylaxis practice
According to the recommendations of the French Anaesthe-
sia and Resuscitation Society [7], the departmental protocol
was to use cefuroxime (1.5 g IVD 30—60min before the inci-
sion and repeat injections of 0.75 g repeated every 2 h when
requested) or vancomycin in the case of allergy (slow per-
fusion of 1 g over 1 h, ≥ 1 h before the incision, no repeat
injections needed).
Compliance was assessed according to the Haute Autorité
de santé [8] guidelines, which recommend:
• injection of double the dose used in antiobiotherapy,
administered 30—60min before the incision;
• repeat injection (at the usual dose) every 2 half-lives,
when necessary;
• repeat injection only for the duration of implantation, and
never for > 48 h.
Practice audits were also performed to study the preop-
erative preparation of a patient’s skin and the physician’s
use of a presurgical alcohol-based hand rub.Statistical analysis
Data were input and analysed using Microsoft Excel® and
R [9]. Means and standard deviations are used to describe
p
ﬁ
w
1327
uantitative variables, and counts and percentages to
escribe qualitative variables. Patients’ characteristics,
ypes of implantation, types of IMD, intervention char-
cteristics, antibiotic prophylaxis, and risk factors were
ompared between patients with SSIs and noninfected
atients using bilateral Fisher’s exact tests or Wilcoxon rank
um tests.
esults
SI surveillance
uring the 6-month study period, 304 interventions that
atisﬁed the inclusion criteria were carried out. Most of
he patients were elderly (mean age 70± 15 years), male
sex ratio 2.2:1), with ﬁrst implantations (73%); 59% were
acemakers and 40% were ICDs (Table 1). Mean duration of
mplantation was 83± 4 (range 7—290)min. The 75th per-
entile value was 103min.
Patients were reviewed at 1, 3, 6 and 12 months
fter surgery by the referring cardiologist. Seven SSIs were
bserved (7/304, 2.3%, 95% conﬁdence interval 0.9—4.7),
ll occurring within 4 months postimplantation (four SSIs
ccurred in < 1 month, three SSIs between 1 and 3.5 months).
The characteristics of patients with an SSI are presented
n Table 2. Of the seven SSIs, ﬁve concerned dual-chamber
acemakers, one a single-chamber automatic AICD and one
triple-chamber AICD. All cases of IMD infection were
reated successfully by prolonged antibiotic treatment,
evice removal and contralateral reimplantation.
As shown in Table 1, three factors were univariately
ssociated with SSIs: (i) history of contralateral IMD implan-
ation (16/297 [5.4%] vs 2/7 [29%] in uninfected and infected
atients, respectively, P < 0.05); (ii) repositioning of genera-
or and/or lead(s) (5/297 [1.7%] vs 2/7 [29%] in noninfected
nd infected patients, respectively, P < 0.006); and (iii)
ntiplatelet or antiaggregant treatment (119/297 [40%] vs
/7 [100%], in noninfected and infected patients, respec-
ively, P < 0.002).
PP in antibiotic prophylaxis
n 13 cases, antibiotic treatment was ongoing at the time of
MD implantation. Antibiotic prophylaxis was recorded in the
emaining 291 patients (cefuroxime, 283 cases; vancomycin,
cases). The time between injection and incision was cor-
ect (i.e. 30—60min before incision [7]) in 153 patients
153/291, 52.6%; Table 3). In three patients (3/291, 1%),
ntibiotics were injected after incision.
Repeated injections of cefuroxime, which were indicated
n 103 cases, were recorded in 94 cases. Unnecessary repeat
njections were given in four patients. The rate of compli-
nce for this variable was thus 95.4% (270/283 patients).
he rates of compliance for each variable of antibiotic use
molecule, timing, repeat injection) and overall compliance
re summarized in Table 4.
The seven patients who developed SSIs had received pro-
hylactic cefuroxime. Of these, three had not received the
rst injection within the correct time period, and another
as not given a second injection (the operation ﬁnished
0min after the time the second injection was due).
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Table 1 Characteristics and risk factors for surgical site infection in a cohort of 304 patients receiving implantable
medical devices.
Cohort (n = 304) Infection status
Uninfected (n = 297) SSI (n = 7) Pa
Age (years) 70± 15 70± 15 68± 14 0.87
Days in hospital 7± 7 6± 7 12± 14 0.15
Male sex 210 (69) 204 (69) 6 (86%) 0.44
Implantation
Total ﬁrst 223 (73) 218 (73) 5 (71%) 1.00
First 205 (92) 202 (93) 3 (60)
Contralateral ﬁrst 18 (8) 16 (7) 2 (40) 0.05
Total reintervention 81 (27) 79 (27) 2 (29)
Change of generator and/or lead(s) 74 (91) 74 (94) 0 (0)
Repositioning of generator and/or lead(s) 7 (9) 5 (6) 2 (100) 0.006
Type of IMD
Total pacemaker 178 (59) 173 (58) 5 (71) 0.74
Single-chamber pacemaker 30 30 (17) 0 (0) 0.78
Dual-chamber pacemaker 127 122 (71) 5 (100)
CRT pacemaker (triple-chamber) 21 21 (12) 0 (0)
Total ICD 121 (40) 119 (40) 2 (29)
Single-chamber ICD 38 37 (31) 1 (50) 1.00
Double-chamber ICD 30 30 (25) 0 (0)
CRT deﬁbrillator (triple-chamber) 53 52 (44) 1 (50)
Total Holter 5 (2) 5 (2) 0 (0)
Intervention as emergency 16 (5) 16 (5) 0 (0) 1.00
Duration of intervention (min) 84± 52 84± 52 82± 57 0.88
ASA class
1 12 (4) 11 (4) 1 (14) 0.45
2 68 (22) 67 (23) 1 (14)
3 132 (43) 129 (43) 3 (43)
4 91 (30) 89 (30) 2 (29)
5 1 (0) 1 (0) 0 (0)
Contamination class
Clean 223 (73) 218 (73) 5 (71) 1.00
Clean contaminated 81 (27) 79 (27%) 2 (29)
NNIS score
0 47 (15) 46 (15) 1 (14) 1.00
1 118 (39) 115 (39) 3 (43)
2 139 (46) 136 (46) 3 (43)
3 0 (0) 0 (0) 0 (0)
Literature-derived risk factors
Anticoagulant and/or antiplatelet treatment 126 (41) 119 (40) 7 (100) 0.002
Valve prosthesis 38 (13) 36 (12) 2 (29) 0.21
Previous resuscitation, intensive care 70 (23) 67 (23) 3 (43) 0.20
Temperature before intervention≥ 37.5 ◦Cb 15 (6) 15 (6) 0 (0) 1.00
Data are given as mean± SD or number (%) unless otherwise stated. ASA: American Society of Anesthesiologists; ICD: implantable
cardioverter deﬁbrillator; IMD: implanted medical device; NNIS: National Nosocomial Infection Surveillance; SD: standard deviation;
SSI: surgical site infection.
a Bilateral Fisher’s exact test for qualitative variables and Wilcoxon rank sum test for age, number of days in hospital and duration of
intervention.
b 43 missing data (42 in uninfected patients and 1 SSI).
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Table 3 Distribution of time between antibiotic injec-
tion and incision.
Time between
antibiotic injection
and incision
Number of
observations
(n = 291)
Percentage
Not recorded 1 0.3
After incision 3 1.0
Before incision
0—10min 34 11.7
11—20min 55 18.9
21—29min 37 12.7
30min—1ha 153 52.6
1 h 01—1h 15min 3 1.0
1 h 16—1h 30min 3 1.0
1 h 31—1h 50min 2 0.7
a As recommended by the French Anaesthesia and Resuscitation
Society [7].
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Iiscussion
nfection after IMD implantation is a serious complication.
hile infection rates showed a decrease from 0.13 to 19.9%
n the 1980s, to 1—6% for pacemakers (3-year follow-up) or
eﬁbrillators (1-year follow-up) [10], a longitudinal study of
edicare beneﬁciaries showed a 124% increase in the rate
f cardiac device infections during the 1990s (0.9% in 1990
o 2.1% in 1999) [11].
A recent 10-year (1994—2004) retrospective study done
n Australia reported an IMD infection rate of 1.6% (including
0.3% rate of endocarditis) [12]. In France, the PEOPLE trial
2000) observed an incidence of 0.68% after IMD implanta-
ion (95% CI 0.47—0.89) after 1 year of follow-up.
In the present study, the overall rate of device infection
2.3%; 95% CI 0.91—4.7%) was statistically higher than the
ate reported in the PEOPLE study (P = 0.006), with compara-
le methods. This discrepancy may be related to the sizes of
he two cohorts (304 vs 6319 patients) or to the noninclusion
n the PEOPLE study of patients with erosive complications,
lthough it has been suggested that an infectious process is
ound in most local device-related complications [13].
Five predictive variables were highlighted in the PEOPLE
tudy: fever before implantation; temporary pacing before
mplantation; device replacement or revision; early reinter-
ention; and absence of antibiotic prophylaxis [3]. Fever
efore surgery was not conﬁrmed as a predictor of SSI in the
resent series, while device replacement and early reinter-
ention were conﬁrmed as signiﬁcant adverse predictors. Of
ote, in the case of impending erosion, a second procedure
s needed to reposition the device. In univariate analysis,
epositioning was signiﬁcantly related to subsequent device
nfection (2/7 cases, P = 0.006), inducing a 20-fold increase
n risk (odds ratio 23.4, 95% CI 3.6—150.5).
Antibiotic prophylaxis is mandatory in our institution,
herefore all patients received some form of preventive
reatment (100% received antibiotic treatment, with a 45%
ate of compliance according to the Haute Autorité de santé
riteria) and the present study could not assess this point.
nterestingly, anticoagulant or antiplatelet therapy use was
330 M. Metais et al.
Table 4 Compliance with recommendations for antibiotic prophylaxis.
Number of patients Compliance
n %
Antibiotic prophylaxis in IMD implantation 291a 291 100
Recommended timing of injection (30—60min before incision) 291 153 53
Repeated injection of cefuroxime when indicated 103 94 91
Single injection of cefuroxime when indicated 180 176 98
Appropriate number of cefuroxime injections 283 270 95
IMD: implanted medical device.
a Eight patients with vancomycin and 283 with cefuroxime prophylaxis.
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ctrongly related to occurrence of infection (P = 0.002), but
nticoagulant or antiplatelet therapy use was not related to
eintervention (P = 0.71).
The impact of the complexity of the device or of the pro-
edure in infectious complications remains controversial.
n a study carried out between 1992 and 1994, Aggarwal
t al. found no signiﬁcant difference in SSI rates between
ingle- or dual-chamber pacemakers [14], whereas Chauhan
t al. [15] reached the opposite conclusion, with SSI rates
f 0.6% for single-chamber pacemakers and 2.1% for dual-
hamber pacemakers. No differences in SSI rates between
ingle-chamber and dual- or triple-chamber pacemakers
ere observed in the present study. Similarly, prolonged
rocedure duration and operator inexperience have been
uggested as predictors of infection in some studies [16,17].
aradoxically, in the present cohort, the mean duration
f implantation was slightly shorter in patients who sub-
equently developed an infection than in those who did
ot (82± 57 vs 84± 52 in infected and uninfected patients,
espectively, P = 0.88). Only one SSI occurred in a triple-
hamber IMD, for which the operation to implant it is the
ongest.
Other risk factors such as diabetes, postoperative
aematoma or operator inexperience remain controversial
6], as they have not been conﬁrmed in the PEOPLE cohort
3]. More recently, statistically signiﬁcant relationships
etween SSIs and fever occurring 24 h after the implanta-
ion, early reintervention, and implantation of more than
wo leads have been demonstrated in the Leiden registry
17].
Two mechanisms are suggested for the development of
SIs: preoperative contamination and postoperative blood-
orne contamination from a distant infectious site such as
he skin, urinary tract or digestive tract [16]. The respec-
ive contribution of each of these mechanisms is unknown.
owever, early infection suggests perioperative contamina-
ion and is best controlled by strict application of infection
ontrol recommendations. In the present study, all SSIs
eveloped within 3 months of device implantation. As
n most studies [6,12,16,18], we isolated exclusively the
taphylococcus genus. Early SSIs or endocarditis (occurring
ithin 2months) are relatedmainly to infection with Staphy-ococcus aureus, whereas in the subacute and chronic forms,
. epidermidis [16] is more prevalent.
The efﬁcacy of preoperative screening for MRSA, already
emonstrated in cardiovascular surgery [19], merits assess-
Rent in the ﬁeld of ICD implantation for patients with risk
actors for long-term colonization by this organism, such as
iabetes, chronic skin ulcers or a previous stay in a resusci-
ation ward or long-term facility.
The crucial relevance of antibiotic prophylaxis and its
iming in the reduction of SSI rates has been amply
emonstrated [20—22]. The relevance of adapting antibiotic
rophylaxis (doses, duration) to demonstrated risk factors
hould be evaluated.
As opposed to other surgical specialities, the objec-
ive here is to address infection with bacteria from the
taphylococcus genus. Prophylaxis with betalactamins, or
ancomycin in the case of a contraindication or suspicion
f MRSA, are recommended. However, similar to other spe-
ialities [23,24], the most stringent criterion to meet is the
iming of the injection. For this reason, the overall compli-
nce rate for antibiotic prophylaxis was found to be only 45%
n the present series.
Preparation of the patient’s skin [19] and presurgical
lcohol-based hand-rub practices [25] were also audited
uring the same period according to national guidelines.
ompliance rates of 43 and 21% for the preparation of the
atient’s skin and hand rubs, respectively, were demon-
trated.
onclusion
ptimal compliance to antibiotic prophylaxis, preoperative
reparation of the patient’s skin and presurgical alcohol-
ased hand rub recommendations were not reached in the
resent series, which demonstrated an SSI rate of 2.3%.
fforts should be paid to obtain full adhesion to preventive
easures in IMD implantation.
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